Contact

Dr. Thomas Borcholte, Chief Business Officer

Tel.: +49 (0)89 - 41 31 38 - 0
E-Mail: licensing@wilex.com

Optimize Product Potential through Co-Development and Commercialization Partnerships

WILEX intends to exploit the full potential of its pipeline products by selectively entering into strategic co-development and commercialisation partnerships.

RENCAREX®* program

The antibody RENCAREX® is currently in a pivotal Phase III trial in the adjuvant treatment of non-metastatic renal cell carcinoma (RCC). To date, no drug has received regulatory approval from the EMEA or the FDA for the adjuvant treatment of non-metastatic RCC.

• WILEX has partnered RENCAREX® for co-development and commercialization in certain countries of South Europe (Spain, Italy, Portugal, Greece, and Andorra) with the Spanish pharmaceutical company Esteve (Press Release). This deal represents the first step of the commercialization and partnering strategy of the company with its lead compound RENCAREX®.
  
• WILEX seeks to partner RENCAREX® with one major pharmaceutical companies for co-development and commercialization.

REDECTANE®*

The diagnostic candidate REDECTANE® is intended to be used as an imaging diagnosis product in planning the surgical therapy of patients with suspected renal cell carcinoma. REDECTANE® is a radioactively labelled form of the antibody WX-G250. If the tumour cells can be targeted by the labelled antibody, the label will accumulate in the tumour tissue. Due to the radioactive labelling, this accumulation can be visualised by means of Positron Emission Tomography (PET). In feasibility study the new antibody based diagnostic imaging agent demonstrates a 100 % positive predictive accuracy. REDECTANE® entered a Phase III registration trial. Patient recruitment is expected to be completed by the end of 2008.

In June 2008 WILEX signed an agreement with Ion Beam Application S.A. for REDECTANE® for the worldwide marketing, distribution and sale as well as for the manufacturing (radio-labelling) (Press Release).

uPA program

According to the company the uPA program is a promising new non-cytotoxic approach in cancer therapy to specifically block tumour metastasis and primary tumour growth in solid cancers. The drug candidates WX-UK1 and MESUPRON®* are being developed for anti-metastatic treatment in a wide variety of solid tumour types.
WILEX holds the worldwide commercialization rights of its uPA program, including the following development candidates:

• Oral uPA and serine protease inhibitor MESUPRON® (in clinical development in cancer patients)
• Several other compounds targeting components of the uPA system (Research)

WILEX seeks to partner its uPA program with one pharmaceutical company on a worldwide basis for co-development and commercialization.

* temporary name while under development